ABBV AbbVie Inc.
Healthcare · Drug Manufacturers - General
250.09
+0.85%
About the company
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
52-week range
Dividend deep dive
AbbVie Inc., a Drug Manufacturer in the Healthcare sector with a market cap of $461.26 billion USD, currently offers a dividend yield of 2.7%. This yield is below its 5-year historical low of 3.18%, suggesting it is overvalued according to yield theory. The company's dividend safety status is rated as "at_risk" for retail dividend investors.
Dividend history
AbbVie has maintained a dividend increase streak of 12 years, qualifying it as a CCC Contender. The company distributes dividends quarterly in January, April, July, and October. Its 3-year dividend compound annual growth rate (CAGR) stands at 5.17%, and its 5-year CAGR is 6.81%. Annual dividends per share have grown from $1.68 USD in 2014 to $6.20 USD in 2024, with projections for $6.56 USD in 2025. This consistent growth profile highlights its commitment to returning capital.
Dividend safety
The company's dividend safety is rated "at_risk," partly due to a high payout ratio of 339.22%, indicating that dividends are not fully covered by earnings per share of $2.04 USD.
Quantic · Free
Read the rest of the safety verdict
Plus the key risks and what to watch next — free, no card.
AI-generated from Quantic's dividend data · Updated 17 Jul 2026 · Information, not financial advice.
Price history
Dividend profile
Yield band A stock's current dividend yield shown against its own range over the past five years — the low, average and high. Near the high end the shares look relatively cheap for the income they pay; near the low end, relatively expensive. It's the picture behind Dividend Yield Theory. Learn more → (5-year)
Payment calendar
Dividend history
Per-share dividend by year
Debt & leverage
Latest reported balance-sheet figures.
Held by 8 investors
Appears in these lists
ABBV qualifies for these curated dividend rankings.
Appears in these comparisons
See how ABBV stacks up against its dividend rivals.
New to dividend investing?
Information, not financial advice.
Quantic · Free
Track ABBV and your whole portfolio
Real yield, dividend safety, net-of-tax income and your path to freedom — free, no broker connection.
Need more? Pro adds portfolios, options income tracking & more AI. See Pro →